AU2019349874A1 - Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof - Google Patents

Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof Download PDF

Info

Publication number
AU2019349874A1
AU2019349874A1 AU2019349874A AU2019349874A AU2019349874A1 AU 2019349874 A1 AU2019349874 A1 AU 2019349874A1 AU 2019349874 A AU2019349874 A AU 2019349874A AU 2019349874 A AU2019349874 A AU 2019349874A AU 2019349874 A1 AU2019349874 A1 AU 2019349874A1
Authority
AU
Australia
Prior art keywords
substitution
binding molecule
seq
antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019349874A
Other languages
English (en)
Inventor
Jieyi Wang
Yi Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyvgen Biopharma Holdings Ltd
Original Assignee
Lyvgen Biopharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyvgen Biopharma Holdings Ltd filed Critical Lyvgen Biopharma Holdings Ltd
Publication of AU2019349874A1 publication Critical patent/AU2019349874A1/en
Assigned to LYVGEN BIOPHARMA HOLDINGS LIMITED reassignment LYVGEN BIOPHARMA HOLDINGS LIMITED Request for Assignment Assignors: Lyvgen Biopharma (Suzhou) Co., Ltd., LYVGEN BIOPHARMA CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019349874A 2018-09-28 2019-09-27 Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof Pending AU2019349874A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/108285 2018-09-28
CN2018010828 2018-09-28
PCT/IB2019/001135 WO2020065409A2 (en) 2018-09-28 2019-09-27 Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AU2019349874A1 true AU2019349874A1 (en) 2021-04-29

Family

ID=69950020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019349874A Pending AU2019349874A1 (en) 2018-09-28 2019-09-27 Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof

Country Status (4)

Country Link
JP (1) JP7626698B2 (https=)
AU (1) AU2019349874A1 (https=)
CA (1) CA3114567A1 (https=)
WO (1) WO2020065409A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512572B (zh) 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
CR20230119A (es) * 2020-08-07 2023-05-16 Genentech Inc Proteínas de fusión del ligando para flt3 y métodos de uso
JP2024500945A (ja) * 2020-12-23 2024-01-10 マクファーレン バーネット インスティテュート フォー メディカル リサーチ アンド パブリック ヘルス リミテッド ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法
WO2024126289A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126294A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
BRPI0417266B8 (pt) * 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
EP2125893A2 (en) * 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2016177771A1 (en) * 2015-05-04 2016-11-10 Apogenix Ag Single-chain cd40-receptor agonist proteins
JP7497953B2 (ja) * 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
AU2016285920A1 (en) * 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
ES2985566T3 (es) * 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada

Also Published As

Publication number Publication date
CA3114567A1 (en) 2020-04-02
WO2020065409A8 (en) 2021-06-17
JP2022503961A (ja) 2022-01-12
WO2020065409A3 (en) 2020-05-07
WO2020065409A2 (en) 2020-04-02
JP7626698B2 (ja) 2025-02-04

Similar Documents

Publication Publication Date Title
US20220372155A1 (en) Anti-cd40 binding molecules and bi-specific antibodies comprising such
JP7626698B2 (ja) 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
US11505615B2 (en) Anti-CD137 antibodies and uses thereof
US12024560B2 (en) Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
WO2020069382A1 (en) Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
US11186648B2 (en) Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof
US11976123B2 (en) Anti-CD40 antibodies and uses thereof
US20230406950A1 (en) Bi-specific antibodies comprising anti-cd137 binding molecules

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ PCT/CN2018/108285 28 SEP 2018 CN

PC1 Assignment before grant (sect. 113)

Owner name: LYVGEN BIOPHARMA HOLDINGS LIMITED

Free format text: FORMER APPLICANT(S): LYVGEN BIOPHARMA CO., LTD.; LYVGEN BIOPHARMA (SUZHOU) CO., LTD.